NanoViricides Inc. Develops Broad-Spectrum Antiviral Amid Rising Measles and MPox Threats

May 14, 2025 — NanoViricides, Inc., a biopharmaceutical company specializing in antiviral treatments, has announced its strategic approach to addressing the increasing global threat of viral infections, particularly measles and MPox. The company, based in West Haven, United States, is listed on the NYSE American exchange and focuses on developing broad-spectrum antivirals using host-mimetic nanomedicine technology.

Recent reports indicate a significant rise in measles cases globally, with a ten-fold increase in annual cases in Europe last year. This surge is compounded by a decline in vaccination rates and an increase in vaccine failure cases, particularly in developed countries. In response, NanoViricides is advancing its clinical-stage drug, NV-387, which is a broad-spectrum, host-mimetic antiviral nanomedicine. This drug is currently the only candidate with potential to combat the measles virus, as there is no approved treatment for measles virus infection.

NanoViricides has initiated an animal efficacy study to evaluate the effectiveness of NV-387 against the measles virus. The company plans to make NV-387 available to licensed physicians, aiming to provide a critical solution in the fight against measles and other viral threats.

In addition to measles, MPox continues to pose a significant global health threat. NanoViricides’ broad-spectrum antiviral strategy is designed to address such pandemics, leveraging its innovative nanomedicine technology that viruses cannot easily evade.

As of May 4, 2025, NanoViricides’ stock closed at $1.25, with a 52-week high of $3.59 and a low of $0.94. The company’s market capitalization stands at $20.8 million, with a price-to-earnings ratio of -1.85, reflecting its current financial standing in the biotechnology sector.

For more information on NanoViricides’ efforts and offerings, visit their website at www.nanoviricides.com .